Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pharmacyclics LLC.
University of Chicago
Hoffmann-La Roche
St. Jude Children's Research Hospital
National Institutes of Health Clinical Center (CC)
University of Colorado, Denver
Dartmouth-Hitchcock Medical Center
Hutchmed
Eli Lilly and Company
Incyte Corporation
M.D. Anderson Cancer Center
Novartis
Werewolf Therapeutics, Inc.
Fred Hutchinson Cancer Center
Thomas Jefferson University
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Massachusetts General Hospital
University of California, Davis
City of Hope Medical Center
University of Washington
Thomas Jefferson University
Baylor College of Medicine
CRISPR Therapeutics
Incyte Corporation
Memorial Sloan Kettering Cancer Center
Acerta Pharma BV
Bayer
National Institutes of Health Clinical Center (CC)
Genmab
Takeda
Universität des Saarlandes
City of Hope Medical Center
Incyte Corporation
Stanford University
Celgene
University of Miami
Pharmacyclics LLC.
University of Washington
Celgene
Roswell Park Cancer Institute
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
National Institutes of Health Clinical Center (CC)
Thomas Jefferson University
Gilead Sciences